Filing Flows › Companies › BridgeBio Pharma › Report card
BridgeBio Pharma earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 5 reports beat the EPS estimate
BridgeBio Pharma (BBIO) beat the analysts' EPS estimate in 2 of its last 5 reports (40%), by -17.7% on average. On report days the stock moved 1.8% in either direction on median (largest 5.8%), rising 20% of the time.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Oct 29, 2026 | −$0.56 | −$0.42 | +24.6% | $353M | +5.8% | +8.0% |
| Q2 2026 | Aug 10, 2026 | −$0.58 | −$0.78 | -33.9% | $244M | -0.9% | -0.6% |
| Q1 2026 | May 7, 2026 | −$0.62 | −$0.84 | -36.2% | $195M | -1.0% | -1.5% |
| Q4 2025 | Feb 24, 2026 | −$0.62 | −$0.94 | -50.6% | $154M | -2.0% | -3.6% |
| Q3 2025 | Oct 29, 2025 | −$0.78 | −$0.72 | +7.7% | $121M | -1.8% | -0.7% |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 5 reports the stock moved 1.8% on median on the day (close to close), the largest move 5.8%.
The next report: what to expect → BridgeBio Pharma: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.